ID   NCC-LGFMS1-C1
AC   CVCL_B0W9
DR   Wikidata; Q108821013
RX   PubMed=34535876;
WW   https://en.cellline.jp/product/ncc-lgfms1-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~149.9 hours (PubMed=34535876).
CC   Sequence variation: Gene fusion; HGNC; 23720; CREB3L2 + HGNC; 4010; FUS; Name(s)=FUS-CREB3L2 (PubMed=34535876).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Rectus abdominis muscle; UBERON=UBERON_0002382.
ST   Source(s): PubMed=34535876
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 9,13
ST   D21S11: 29,33.2
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C45202; Low grade fibromyxoid sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 30-01-24; Version: 5
//
RX   PubMed=34535876; DOI=10.1007/s13577-021-00612-1;
RA   Yoshimatsu Y., Noguchi R., Sin Y., Tsuchiya R., Ono T., Sei A.,
RA   Sugaya J., Iwata S., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of NCC-LGFMS1-C1: a novel
RT   patient-derived cell line of low-grade fibromyxoid sarcoma.";
RL   Hum. Cell 34:1919-1928(2021).
//